Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer

Inclusion Criteria

• •1. Males or females aged ≥18 to ≤75 years at the time of signing the ICF
• •2. Histologically or cytologically confirmed diagnosis of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with documented EGFR Exon 19 deletion or Exon21 L858R mutation.
• •3. Received one prior epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy in the locally advanced, or metastatic setting, either as monotherapy or in combination with other agents; Received one prior platinum based chemotherapy in the locally advanced, or metastatic setting, either prior to TKI, in combination with TKI, or after TKI therapy.
• •4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
• •5. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, that has not been previously irradiated.
• •6. Central nervous system (CNS) metastasis, these should be clinically asymptomatic or stable after definitive treatment.
• •7. Current, historical, or suspected interstitial lung disease (ILD)/pneumonitis.